Why It Matters

The Supreme Court's unanimous decision in Hikma v. Amarin fundamentally altered the legal landscape for generic pharmaceutical manufacturers, imposing a stricter standard for what constitutes patent infringement liability and potentially clearing a path for lower-cost alternatives to reach patients sooner.

According to a recent Congressional Research Service report, the June 4 ruling reversed the U.S. Court of Appeals for the Federal Circuit and rejected what the court described as the "recent approach" taken in earlier cases, including GSK v. Teva. Justice Ketanji Brown Jackson authored the opinion, holding that to sustain an inducement claim, a complaint must allege affirmative actions or statements designed to encourage infringement, not merely statements that could stimulate infringing conduct.

The decision narrows the circumstances under which brand-name manufacturers can sue generic competitors, potentially accelerating generic entry and lowering medication costs. Yet the underlying tension between patent protection and generic competition persists, leaving Congress to decide whether legislative action is needed.

When a brand-name drug has multiple approved uses and only some are protected by patents, generic manufacturers can seek FDA approval for the unpatented uses through a "skinny label" that omits the patented indications.

Brand-name manufacturers have responded by suing generic manufacturers for allegedly inducing patent infringement through marketing statements, press releases and other communications. In GSK v. Teva, the Federal Circuit upheld a jury verdict finding a generic manufacturer liable for inducement even though it carved out the label language covering the patented uses and did not directly instruct physicians to prescribe the generic for those uses. The Supreme Court's decision rejects that approach, requiring concrete allegations of intent and affirmative conduct rather than speculation about how statements might be interpreted.

The Big Picture

The dispute arose from the development of Vascepa. Amarin received FDA approval for the drug in 2012 to treat severe hypertriglyceridemia before later obtaining approval for an additional cardiovascular indication protected by patents.

Hikma filed an abbreviated new drug application using a skinny label seeking approval only for the unpatented severe hypertriglyceridemia indication. The FDA approved Hikma's generic product in 2020. Amarin later sued, alleging Hikma's press releases describing the product as "generic Vascepa" or a "generic equivalent," together with statements referencing overall Vascepa sales, were intended to induce physicians to prescribe the generic for the patented cardiovascular use.

The Federal Circuit had previously found similar conduct actionable. In GSK v. Teva, a generic manufacturer carved out patented uses from its label but still faced inducement liability.

The Supreme Court rejected that reasoning. The opinion held that Hikma's label could not constitute an affirmative act of inducement because federal law requires a generic label to match the brand-name label except for the carved-out indications. Describing a product as a generic equivalent, the court concluded, is truthful and consistent with standard industry practice—not an affirmative effort to encourage patent infringement.

Critically, the Court applied the Twombly/Iqbal pleading standard, requiring complaints to plausibly allege facts demonstrating affirmative encouragement of infringement. Allegations that statements merely could encourage infringing conduct were insufficient. The opinion emphasized that the proper inquiry is the defendant's affirmative conduct and intent, not how third parties might interpret those actions.

Political Stakes

The Association for Accessible Medicines, which represents generic and biosimilar manufacturers, called the ruling an affirmation that affordable medicines can reach patients without unnecessary legal barriers.

The opinion also made clear that affirmative, explicit encouragement to infringe can still give rise to liability, preserving protections for patent holders when generic manufacturers cross that line.

The Skinny Labels, Big Savings Act, introduced in the 119th Congress, would establish a statutory safe harbor from patent infringement liability for generic and biosimilar manufacturers using FDA-approved skinny labels. The legislation would specify that describing a generic drug as therapeutically equivalent to a brand-name drug does not constitute patent infringement.

The Bottom Line

The Hikma v. Amarin decision reinforces Congress' original intent that generic manufacturers should be able to compete for unpatented uses without automatically incurring liability for how physicians prescribe their products. At the same time, it leaves unresolved the broader conflict between patent protection and generic competition because state drug-substitution laws can still result in skinny-labeled generics being dispensed for patented uses.

Patent holders must now show explicit, affirmative efforts to encourage infringement rather than relying on allegations that truthful statements could indirectly promote infringing use. While the Supreme Court tightened the legal standard for inducement claims, Congress may still determine that a statutory safe harbor is necessary to provide greater certainty for both generic manufacturers and brand-name drug developers.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article